Ligand expands tech offering with $516 Pfenex acquisition

San Diego biopharma Ligand Pharmaceuticals is acquiring Pfenex, a biotech based in California, in a deal worth up to $516 million.

The acquisition will provide Ligand with access to a proprietary, protein expression technology that is utilised in various commercial and development-stage biopharmaceutical programs.

It will also provide numerous major collaborations with major pharma players for treatments and vaccines – including Merck, Jazz Pharmaceuticals, Serum Institute of India and Alvogen.

Moreover, the deal gives Legand a atate-of-the-art process development operation located in San Diego with scalable equipment and engineering capabilities designed to serve the world’s largest pharmaceutical companies.

“The acquisition holds potential to have a significantly positive scientific and financial impact on our business in the short and long term, similar to how our Captisol and OmniAb acquisitions have played out,” said Ligand CEO, John Higgins.

“Pfenex will add an established, proven protein expression platform to Ligand that is highly complementary to our essential, proprietary drug discovery and formulation technologies.

“We are confident we will be able to quickly and efficiently grow the Pfenex business, along with our core existing technologies.

“It has been a very positive experience working with the Pfenex executive leadership and senior scientists while we put this deal together. We look forward to welcoming the talented Pfenex team to Ligand.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Boehringer & Click to develop digital therapeutic for schizophrenia

Boehringer Ingelheim and Click Therapeutics will together develop and commercialise of a prescription-based digital therapeutic for schizophrenia. It will utilise cognitive and neurobehavioral mechanisms delivered...

Huadong Medicine & Exscientia to accelerate oncology drug discovery with AI

Exscientia, an AI drug discovery company, and Chinese pharma firm, Huadong Medicine, have partnered to accelerate the discovery of breakthrough small-molecule therapeutics targeted at...

Celltrion given the go-ahead for anti-COVID-19 antibody trial

Celltrion’s Investigational New Drug (IND) application for a Phase II/III pivotal clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, has been approved...

Search for new cancer treatments get £8m genetic boost

Projects to find new treatments for cancer, using whole genome sequencing, have received a £8 million funding boost from UK Research and Innovation (UKRI). Despite...

Mylan acquiring Aspen’s European thrombosis business

Mylan is expanding its complex injectables offering and presence in hospitals with the €641.9 million acquisition of Aspen Pharmacare's thrombosis business in Europe. The portfolio...

Related news

Merck takes $1bn stake in Seattle Genetics as part of oncology collaboration

Merck is acquiring a $1 billion stake in Seattle Genetics has part of two new strategic oncology collaborations between the two companies. The companies will...

Boehringer & Click to develop digital therapeutic for schizophrenia

Boehringer Ingelheim and Click Therapeutics will together develop and commercialise of a prescription-based digital therapeutic for schizophrenia. It will utilise cognitive and neurobehavioral mechanisms delivered...

Huadong Medicine & Exscientia to accelerate oncology drug discovery with AI

Exscientia, an AI drug discovery company, and Chinese pharma firm, Huadong Medicine, have partnered to accelerate the discovery of breakthrough small-molecule therapeutics targeted at...

Celltrion given the go-ahead for anti-COVID-19 antibody trial

Celltrion’s Investigational New Drug (IND) application for a Phase II/III pivotal clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, has been approved...